For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240425:nRSY9230La&default-theme=true
RNS Number : 9230L LungLife AI, INC 25 April 2024
LungLife AI, Inc.
(the "Company" or "LungLife")
Publication of Annual Report and Accounts & Notice of AGM
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces that the Annual Report and Accounts, Notice of Annual
General Meeting ("AGM"), Form of Direction and associated Form of Proxy are
now available on the Company's website and will be posted to those
shareholders who have opted out of electronic communications today.
The documents are available here:
lunglifeai.com/investors/financial-information-documents-presentations/
(https://lunglifeai.com/investors/financial-information-documents-presentations/)
The Company's AGM will be held at 4:00 P.M. (BST) on 5 June 2024, at Investec
Bank plc, 30 Gresham Street, London, EC2V 7QP. The Board will make
arrangements for shareholders to listen to proceedings remotely should they
wish to do so. The Company will announce details of how to listen to the
meeting remotely and any other significant changes to the meeting arrangements
via RNS and on LungLife's website at investors.lunglifeai.com/
(https://investors.lunglifeai.com/)
Shareholders are strongly encouraged to vote by proxy, whether or not you plan
to attend the Company's Annual General Meeting in person. You may register
your votes on the resolutions of the Annual General Meeting by completing and
returning the proxy form that accompanies this Notice in accordance with the
instructions printed on the proxy form.
If shareholders' holding of Common Shares is by way of dematerialised
depository interests representing underlying Common Shares ("Depository
Interests"), they can vote through the CREST system or by returning a Form of
Instruction to the Depositary. Further instructions are set out in the Notes
to the Notice of Annual General Meeting.
The resolutions to be proposed at the Annual General Meeting are summarised in
the Notice of AGM.
The results of voting on the resolutions will be announced via a regulatory
information service and posted on the Company's website as soon as practicably
possible after the AGM.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com (https://www.lunglifeai.com/)
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Joint Broker) Tel: +44 (0)20 7597 5970
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202
Tom Nicholson / Cameron Duncan
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
(mailto:LungLifeAI@walbrookpr.com)
Stephanie Cuthbert / Alice Woodings / Phillip Marriage Mob: 07980 541 893 / 07407 804 654 / 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)
Our Purpose is to be a driving force in the early detection to lung cancer.
Our Vision is to invert the 20:80 ratio such that in years to come at least
80% of lung cancer is detected early.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NOAQKQBBABKDDQB